BioIVT has announced that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.
BioIVT has announced in a Sep. 24, 2019 press release that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.
As part of the platform, BioIVT will partner up with other service providers in the goal of progressing preclinical drug discovery and increase success rates. BioIVT’s PHASEZERO research services team will be used to provide support in the generation of human tissue-based target validation data as well as the characterization of novel therapeutics.
“BioIVT is dedicated to supporting the research community by providing expertise in human tissue-based approaches that deliver target and biomarker validation data and by developing fit-for-purpose assays that enable characterization of novel therapeutics to accelerate drug discovery and development,” said Amanda Woodrooffe, vice-president and general manager at BioIVT UK, in the press release. “We are delighted to join Medicines Discovery Catapult’s Discovery Services Platform and be able to provide our expertise, access to ethically-sourced human biospecimens, and innovative approaches to support UK enterprises.”
Source: BioIVT
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Your Ultimate Guide for CMC Testing Support for Gene and Cell Therapy
November 21st 2024Explore the complexities of gene and cell therapy development with our comprehensive guide to Chemistry, Manufacturing, and Controls (CMC) testing. Learn how our expertise ensures the safety, potency, and quality of advanced therapies, supporting your journey from product development through regulatory approval.